Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Merck KGaA Rebif Faces Irreversible Decline; Avelumab Update Seen Soon

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales of the German multinational’s best-selling MS product sharply declined in the second quarter, but higher investment is likely to boost its research pipeline of early- and late-stage products.

Advertisement

Related Content

Merck KGaA Buys Sigma-Aldrich To Boost Lab Business, Expand Footprint

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register